
Opinion|Videos|March 21, 2025
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
















